All In Biotech

Drug Trial Radar · NCT07086677

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

380

Actual

Start

Jul 22, 2025

Primary completion

Oct 21, 2027

Study completion Oct 21, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years, up to 84 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to two doses of study vaccine or comparator and take part in follow-up visits. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during clinic visits.

Conditions

  • Streptococcus Pneumoniae

Interventions

  • PG4 vaccine in Buffer 1 with low dose PA-001Biological

    Multivalent pneumococcal conjugate vaccine

  • PG4 in Buffer 1 with low dose PA-002Biological

    Multivalent pneumococcal conjugate vaccine

  • PG4 in Buffer 1 with high dose PA-001Biological

    Multivalent pneumococcal conjugate vaccine

  • PG4 vaccine in Buffer 1 with high dose PA-002Biological

    Multivalent pneumococcal conjugate vaccine

  • PG4 vaccine in Buffer 2Biological

    Multivalent pneumococcal conjugate vaccine

  • 20-valent pneumococcal conjugate vaccineBiological

    (20vPnC)

  • Saline injectionBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting prespecified local reactions after each dose.Time frame: Within 7 days after each study intervention.
  2. Percentage of participants reporting prespecified systemic reactions after each dose.Time frame: Within 7 days after each study intervention.
  3. Percentage of participants reporting adverse events.Time frame: From signing of the ICD to 1 month after last study intervention.
  4. Percentage of participants reporting serious adverse events.Time frame: From signing of the ICD to 6 months after the last study intervention.
  5. Percentage of participants reporting serious adverse events.Time frame: From signing of the ICD to 12 months after the last study intervention.
  6. Percentage of participants with abnormal hematology and chemistry laboratory values.Time frame: Within 2 weeks after each study intervention.

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Orange County Research Center

    Lake Forest, California

  • Peninsula Research Associates

    Rolling Hills Estates, California

  • Finlay Medical Research

    Greenacres City, Florida

  • Indago Research & Health Center, Inc.

    Miami Lakes, Florida

  • Johnson County Clinical Trials

    Lenexa, Kansas

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO

    Springfield, Missouri

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center

    Springfield, Missouri

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO

    Springfield, Missouri

  • Velocity Clinical Research, Omaha

    Omaha, Nebraska

  • Upstate Global Health Institute

    East Syracuse, New York

  • NYU Langone Health Vaccine Center

    New York, New York

  • Duke Vaccine and Trials Unit

    Durham, North Carolina

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • Headlands Horizons, LLC dba Headlands Research-Brownsville

    Brownsville, Texas

  • Valley Regional Medical Center

    Brownsville, Texas

  • LabCorp

    Houston, Texas

  • IMA Clinical Research San Antonio

    San Antonio, Texas

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research

    Tomball, Texas

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.